Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;101(6):1287-1289.
doi: 10.1016/j.kint.2022.03.005. Epub 2022 Mar 14.

Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses

Okan Cinkilic  1 , Moritz Anft  2 , Arturo Blazquez-Navarro  3 , Toni L Meister  4 , Toralf Roch  3 , Ulrik Stervbo  2 , Stephanie Pfaender  4 , Timm H Westhoff  2 , Nina Babel  5
Affiliations

Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses

Okan Cinkilic et al. Kidney Int. 2022 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of humoral and cellular immunity of hemodialysis patients vaccinated with 3 (HDP3x) or 4 (HDP4x) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses. Isolated serum samples from hemodialysis patients, vaccinated with 3 doses (n = 40) or 4 doses (n = 19), were analyzed for (a) titers (IU/ml) of binding antibodies against SARS-CoV-2 wild-type (WT) glycoprotein S and (b) omicron-specific neutralizing antibodies (ND50). (c) Comparison of omicron-specific neutralizing antibodies (ND50) after the third doses (T1, respectively), after 12 weeks (HDP3x, T2), or after the fourth doses (HDP4x, T2). Correlation between titers of SARS-CoV-2 WT binding and omicron-specific neutralizing antibodies (d) and receiver operating characteristic curve (e) for the predictive capacity of binding antibody titers against WT glycoprotein S for strong (>100 ND50) WT-specific (blue) and omicron-specific (yellow) neutralizing response, including the value for the area under the curve (AUC). (f,g) Isolated peripheral blood mononuclear cells from hemodialysis patients, vaccinated with 3 doses (HDP3x; n = 19) or 4 doses (HDP4x; n = 18), were stimulated for 16 hours with 1 μg/ml SARS-CoV-2 overlapping peptide pool from WT (left box plots) or the mutated regions of SARS-CoV-2 omicron lineage (O; right box plots). SARS-CoV-2–reactive T helper cells were identified as life/dead-marker–CD3+CD4+CD137+CD154+ (f), and SARS-CoV-2–reactive cytotoxic T cells were identified as life/dead-marker–CD3+CD8+CD137+ (g). In all box plots, red corresponds to the patients who received only 3 doses and blue to those who received all 4 doses; light colors refer to the time point after the third dose, whereas dark colors denote the time point after the fourth dose or 12 weeks after the third. Groups were compared using 2-sided, unpaired Mann-Whitney U-test, except for (c), where Wilcoxon signed-rank paired test was employed; the correlation (d) was evaluated employing the Pearson correlation coefficient. P ≤ 0.050 was defined as significant. ELISA, enzyme-linked immunosorbent assay.
See this image and copyright information in PMC

References

    1. Garcia-Beltran W.F., St Denis K.J., Hoelzemer A., et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell. 2022;185:457–466.e4. - PMC - PubMed
    1. Munro A.P.S., Janani L., Cornelius V., et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258–2276. - PMC - PubMed
    1. Caillard S., Thaunat O., Benotmane I. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series. Ann Intern Med. 2022;175:455–456. - PMC - PubMed
    1. Kamar N., Abravanel F., Marion O., et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Network Open. 2021;4 - PMC - PubMed
    1. Roch T., Rohn B., Blazquez-Navarro A., et al. A vector-based vaccine dose after 3 doses of mRNA-based COVID-19 vaccination does not substantially improve humoral SARS-CoV-2 immunity in renal transplant recipient. Kidney Int Rep. 2022;7:932–934. - PMC - PubMed

Publication types

Supplementary concepts